VALN
Valneva SE
NASDAQ · Healthcare · Biotechnology · FR
$6.89
−2.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 143.5M | 174.7M | 169.6M | 153.7M | 361.3M |
| Cost of Revenue | 120.0M | 107.1M | 98.5M | 100.9M | 324.4M |
| Gross Profit | 23.5M | 67.5M | 71.0M | 52.8M | 36.9M |
| Operating Expenses | |||||
| R&D Expense | 83.3M | 85.3M | 74.1M | 59.9M | 104.9M |
| SG&A Expense | 64.2M | 74.7M | 95.1M | 96.6M | 57.6M |
| General & Admin Expense | 33.7M | 37.3M | 42.8M | 47.8M | 34.1M |
| Selling & Marketing Expense | 30.5M | 37.4M | 52.4M | 48.8M | 23.5M |
| Other Expenses | (8.0M) | (10.8M) | (111.5M) | (21.5M) | (12.2M) |
| Total Operating Expenses | 139.6M | 149.2M | 57.7M | 134.9M | 150.3M |
| Cost and Expenses | 259.7M | 256.3M | 156.2M | 235.8M | 474.7M |
| Operating Income (EBIT) | (116.1M) | (81.6M) | 13.3M | (82.1M) | (113.4M) |
| Non-Operating | |||||
| Interest Income | 1.9M | 1.8M | 2.4M | 1.2M | 260.0K |
| Interest Expense | 40.7M | 41.9M | 24.0M | 23.3M | 19.1M |
| Net Interest Income | (38.8M) | (40.1M) | (21.6M) | (22.1M) | (18.8M) |
| Other Non-Op Income/Expense | (42.0M) | (32.5M) | (24.8M) | (16.5M) | (31.4M) |
| Non-Operating Income (excl Interest) | (1.0M) | (9.4M) | 832.0K | (6.8M) | 12.3M |
| EBT (Pre-Tax Income) | (158.1M) | (114.1M) | (11.5M) | (98.6M) | (144.8M) |
| Income Tax Expense | 70.6K | 1.1M | 761.0K | 2.8M | (1.5M) |
| Bottom Line | |||||
| Net Income | (158.2M) | (115.2M) | (12.2M) | (101.4M) | (143.3M) |
| Earnings from Cont. Ops | (158.2M) | (115.2M) | (12.2M) | (101.4M) | (143.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (158.2M) | (115.2M) | (12.2M) | (101.4M) | (143.3M) |
| Per Share | |||||
| Basic EPS | ($1.82) | ($1.32) | ($0.17) | ($1.46) | ($2.48) |
| Diluted EPS | ($1.82) | ($1.32) | ($0.17) | ($1.46) | ($2.48) |
| Revenue Per Share | $1.51 | $2.08 | $2.41 | $2.22 | $6.26 |
| Shares | |||||
| Basic Shares Outstanding | 94.8M | 84.1M | 70.3M | 69.3M | 57.7M |
| Diluted Shares Outstanding | 94.8M | 84.1M | 70.3M | 69.3M | 57.7M |
| Profitability Metrics | |||||
| EBITDA | (94.3M) | (50.5M) | 32.1M | (57.7M) | (104.7M) |
| D&A | 20.8M | 21.8M | 19.6M | 17.6M | 21.0M |
| EBIT | (115.1M) | (72.2M) | 12.5M | (75.3M) | (125.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026